Kelly E Rentscher1, Judith E Carroll1, Mark B Juckett2,3, Christopher L Coe4, Aimee T Broman5, Paul J Rathouz6, Peiman Hematti2,3, Erin S Costanzo3,7. 1. Department of Psychiatry and Biobehavioral Sciences, Cousins Center for Psychoneuroimmunology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA. 2. Department of Medicine, Division of Hematology/Oncology, University of Wisconsin-Madison, Madison, WI, USA. 3. Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA. 4. Department of Psychology, University of Wisconsin-Madison, Madison, WI, USA. 5. Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA. 6. Department of Population Health, University of Texas at Austin, Austin, TX, USA. 7. Department of Psychiatry, University of Wisconsin-Madison, Madison, WI, USA.
Abstract
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a widely used treatment for hematologic cancers, with survival rates ranging from 25% to 78%. Known risk factors for chronic graft-versus-host disease (cGVHD), a serious and common long-term complication, disease relapse, and mortality following HCT have been identified, but much of the variability in HCT outcomes is unexplained. Biobehavioral symptoms including depression, sleep disruption, and fatigue are some of the most prevalent and distressing for patients; yet research on biobehavioral risk factors for HCT outcomes is limited. This study evaluated patient-reported depression, sleep disruption, and fatigue as risk factors for cGVHD, disease relapse, and mortality. METHODS: Adults receiving allogeneic HCT for a hematologic malignancy (N = 241) completed self-report measures of depression symptoms, sleep quality, and fatigue (severity, interference) pre-HCT and 100 days post-HCT. Clinical outcomes were monitored for up to 6 years. RESULTS: Cox proportional hazard models (2-tailed) adjusting for patient demographic and medical characteristics revealed that high pre-HCT sleep disruption (Pittsburgh Sleep Quality Index >9; hazard ratio [HR] = 2.74, 95% confidence interval [CI] = 1.27 to 5.92) and greater post-HCT fatigue interference (HR = 1.32, 95% CI = 1.05 to 1.66) uniquely predicted increased risk of mortality. Moderate pre-HCT sleep disruption (Pittsburgh Sleep Quality Index 6-9) predicted increased risk of relapse (HR = 1.99, 95% CI = 1.02 to 3.87). Biobehavioral symptoms did not predict cGVHD incidence. CONCLUSIONS: Biobehavioral symptoms, particularly sleep disruption and fatigue interference, predicted an increased risk for 6-year relapse and mortality after HCT. Because these symptoms are amenable to treatment, they offer specific targets for intervention to improve HCT outcomes.
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a widely used treatment for hematologic cancers, with survival rates ranging from 25% to 78%. Known risk factors for chronic graft-versus-host disease (cGVHD), a serious and common long-term complication, disease relapse, and mortality following HCT have been identified, but much of the variability in HCT outcomes is unexplained. Biobehavioral symptoms including depression, sleep disruption, and fatigue are some of the most prevalent and distressing for patients; yet research on biobehavioral risk factors for HCT outcomes is limited. This study evaluated patient-reported depression, sleep disruption, and fatigue as risk factors for cGVHD, disease relapse, and mortality. METHODS: Adults receiving allogeneic HCT for a hematologic malignancy (N = 241) completed self-report measures of depression symptoms, sleep quality, and fatigue (severity, interference) pre-HCT and 100 days post-HCT. Clinical outcomes were monitored for up to 6 years. RESULTS: Cox proportional hazard models (2-tailed) adjusting for patient demographic and medical characteristics revealed that high pre-HCT sleep disruption (Pittsburgh Sleep Quality Index >9; hazard ratio [HR] = 2.74, 95% confidence interval [CI] = 1.27 to 5.92) and greater post-HCT fatigue interference (HR = 1.32, 95% CI = 1.05 to 1.66) uniquely predicted increased risk of mortality. Moderate pre-HCT sleep disruption (Pittsburgh Sleep Quality Index 6-9) predicted increased risk of relapse (HR = 1.99, 95% CI = 1.02 to 3.87). Biobehavioral symptoms did not predict cGVHD incidence. CONCLUSIONS: Biobehavioral symptoms, particularly sleep disruption and fatigue interference, predicted an increased risk for 6-year relapse and mortality after HCT. Because these symptoms are amenable to treatment, they offer specific targets for intervention to improve HCT outcomes.
Authors: G Socié; J V Stone; J R Wingard; D Weisdorf; P J Henslee-Downey; C Bredeson; J Y Cahn; J R Passweg; P A Rowlings; H C Schouten; H J Kolb; J P Klein Journal: N Engl J Med Date: 1999-07-01 Impact factor: 91.245
Authors: Julienne E Bower; Patricia A Ganz; Michael R Irwin; Lorna Kwan; Elizabeth C Breen; Steve W Cole Journal: J Clin Oncol Date: 2011-08-08 Impact factor: 44.544
Authors: Areej R El-Jawahri; Lara N Traeger; Kailyn Kuzmuk; Justin R Eusebio; Harry B Vandusen; Jennifer A Shin; Tanya Keenan; Emily R Gallagher; Joseph A Greer; William F Pirl; Vicki A Jackson; Karen K Ballen; Thomas R Spitzer; Timothy A Graubert; Steven L McAfee; Bimalangshu R Dey; Yi-Bin A Chen; Jennifer S Temel Journal: Cancer Date: 2014-12-02 Impact factor: 6.860
Authors: Xin Shelley Wang; Qiuling Shi; Lori A Williams; Charles S Cleeland; Gary M Mobley; James M Reuben; Bang-Ning Lee; Sergio A Giralt Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: A M Nelson; C L Coe; M B Juckett; M E Rumble; P J Rathouz; P Hematti; E S Costanzo Journal: Bone Marrow Transplant Date: 2014-08-18 Impact factor: 5.483
Authors: Ashley M Nelson; Heather S L Jim; Brent J Small; Taiga Nishihori; Brian D Gonzalez; Julie M Cessna; Kelly A Hyland; Meredith E Rumble; Paul B Jacobsen Journal: Bone Marrow Transplant Date: 2017-12-21 Impact factor: 5.483
Authors: Jennifer M Knight; Mallory R Taylor; Kelly E Rentscher; Elisabeth C Henley; Hannah A Uttley; Ashley M Nelson; Lucie M Turcotte; Natalie S McAndrew; Hermioni L Amonoo; Lathika Mohanraj; Debra Lynch Kelly; Erin S Costanzo Journal: Front Immunol Date: 2022-07-05 Impact factor: 8.786
Authors: Andrew Kirvin-Quamme; Meredith E Rumble; Lisa Cadmus-Bertram; Mark B Juckett; Paul J Rathouz; Gwynneth Schell; Natalie S Callander; Peiman Hematti; Erin S Costanzo Journal: Contemp Clin Trials Commun Date: 2022-05-28